Although many agents are used for each of the processes in ALS pathogenesis, riluzol and edaravone are the agents that have found their place in certain countries.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:The pathogenesis of the prototype of motor neuron diseases, Amyotrophic Lateral Sclerosis (ALS), is not fully understood and the lack of a satisfactory treatment of the disease makes the diagnosis process worrying for the patient and the physician.
📊
Key Findings & Data:The pathogenesis of the prototype of motor neuron diseases, Amyotrophic Lateral Sclerosis (ALS), is not fully understood and the lack of a satisfactory treatment of the disease makes the diagnosis process worrying for the patient and the physician.
💡
Conclusion & Impact:Although many agents are used for each of the processes in ALS pathogenesis, riluzol and edaravone are the agents that have found their place in certain countries.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:ALS · riluzol · edaravone
Abstract
The pathogenesis of the prototype of motor neuron diseases, Amyotrophic Lateral Sclerosis (ALS), is not fully understood and the lack of a satisfactory treatment of the disease makes the diagnosis process worrying for the patient and the physician. Although many agents are used for each of the processes in ALS pathogenesis, riluzol and edaravone are the agents that have found their place in certain countries.
Özet
Motor nöron hastalığının prototipi olan Amiyotrofik lateral Skleroz (ALS) patogenezinin tam olarak anlaşılamamış olması ve hastalığın yüz güldürücü bir tedavisinin olmaması tanı sürecini hasta ve hekim için endişe verici hale getirmektedir. ALS patogenezinde yer alan süreçlerin her birine ilişkin bir çok farklı ajan denense de günümüzde belli ülkelerde onay alarak kendine yer bulmuş olan ajanlar riluzol ve edaravondur.
G. Bensimon, L. Lacomblez, and V. Meininger the ALS/Riluzole Study Group.A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis.N Engl J Med 1994
DOI: 10.1056/NEJM199403033300901 2.Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis.Lancet. 1996 May 25
347(9013):1425-31. 3.Yanagisawa N, Tashiro K, Tohgi H, et al. Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan. Igakuno Ayumi. 1997
851–866. 4.Bensimon G, Lacomblez L, Delumeau JC, et al
Riluzole/ALS Study Group II. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002
Quality Standards Subcommittee of the American Academy of Neurology.Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 2009 Oct 13
73(15):1218-26. doi: 10.1212/WNL.0b013e3181bc0141. 6.Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. Eur J Neurol. 2012
19(3):360–375. 7.Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 1997 Sep
49(3):657-9. 8.Dorst J, Ludolph AC, Huebers A.Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis.Ther Adv Neurol Disord. 2017 Oct 9
1756285617734734. doi: 10.1177/1756285617734734. eCollection 2018. 9.Watanabe T, Yuki S, Egawa M, Nishi H.Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions.J Pharmacol Exp Ther. 1994 Mar
268(3):1597-604. 10.Ikeda K, Iwasaki Y, Kinoshita M. Treatment of wobbler mice with free radical scavenger.Elsevier Science,Amsterdam,Oxford,2001
Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis(Phase II